How Israeli Cardiovascular Innovation Transformed Into Multi-Billion Exits
The Innovation in Cardiovascular Interventions conference in Israel has driven over seven billion dollars in global medical exits, connecting clinical innovators with international giants.

For over three decades, the Innovation in Cardiovascular Interventions conference has served as a premier global platform for advancing cardiovascular medicine in Israel. Founded under the leadership of Professor Chaim Lotan and Professor Rafael Beyar, the conference unites physicians, researchers, entrepreneurs, investors, and executives from international medical device corporations.
Building a Global Health Tech Ecosystem
Over the years, the conference has fostered a fertile ecosystem where groundbreaking clinical ideas mature into commercial technologies and multi-million-dollar exits. The unique strength of the conference lies in bridging real clinical needs with technological solutions, offering early-stage companies a direct stage to present their developments to global decision-makers. Major international corporations send their senior executives to Israel annually to scout promising technologies, transforming strategic networking venues into central transaction arenas.
Landmark Acquisitions and Milestones
Numerous Israeli companies presented at the conference have evolved into global cardiovascular market leaders, driving an impressive wave of acquisitions across decades. Early pioneers in the 1990s included Instent, developer of the first metallic stents acquired by Medtronic, and Biosense, pioneer of electrical mapping and arrhythmia treatment acquired by Johnson & Johnson.
The early 2000s saw a continuation of this momentum with Ventor Technologies, developer of a flow-dynamics-based aortic valve acquired by Medtronic; MediGuide, creator of vascular navigation acquired by St. Jude Medical; and PVT, a catheter-based aortic valve pioneer acquired by Edwards Lifesciences. Valtech, which developed the Cardioband system for transcatheter mitral and tricuspid valve repair, was acquired by Edwards Lifesciences in 2017 in a deal worth hundreds of millions of dollars.
Robotics, Artificial Intelligence, and Recent Exits
Corindus Vascular Robotics, born from a collaboration between the Technion, Rambam Health Care Campus, and Israeli entrepreneurs, developed a robotic system for radiation-protected, remote-controlled catheterizations. In 2019, the company was acquired as a unicorn by Siemens Healthineers in one of the largest cardiovascular exits globally. Innovalve, a developer of an innovative transcatheter mitral valve founded by Israeli cardiac surgeons, was acquired by Edwards Lifesciences in 2024 for hundreds of millions of dollars.
Additional recent milestones include V-Wave, developer of a heart failure shunt acquired by Johnson & Johnson in 2024; Vectorius, creator of an implantable pressure sensor for heart failure monitoring acquired by Edwards Lifesciences; and CathWorks, which developed an AI and image-processing technology for functional evaluation of coronary stenoses without invasive pressure wires, acquired by Medtronic in a multi-hundred-million-dollar transaction. Furthermore, Sonivie developed a renal denervation ultrasound system for hypertension treatment, later acquired by Boston Scientific.
Economic Impact and Future Outlook Ahead of ICI 2026
Cumulative cardiovascular exits stemming from this ecosystem have surpassed 7 billion dollars, injecting substantial capital into the national economy while cultivating seasoned managers, international engineers, and successive generations of entrepreneurs.
Looking forward to the upcoming ICI 2026 conference, Professor Chaim Lotan and Professor Rafael Beyar emphasized:
"Even in these challenging times, the spirit of entrepreneurship, creativity, and boundary-pushing innovation of Israeli cardiovascular technology, as expressed through the conference, ensures that we will continue to spearhead significant breakthroughs."
Beyond transactions, the conference establishes a continuous growth trajectory spanning clinical conception, funding attraction, scientific research, and strategic collaboration. Hundreds of additional Israeli cardiovascular companies currently operate across various developmental stages, positioning the local tech sector for its upcoming wave of global exits.





